ES2325344A1 - Inhibidores de angiogenesis multifuncionales y multivalentes. - Google Patents

Inhibidores de angiogenesis multifuncionales y multivalentes. Download PDF

Info

Publication number
ES2325344A1
ES2325344A1 ES200402635A ES200402635A ES2325344A1 ES 2325344 A1 ES2325344 A1 ES 2325344A1 ES 200402635 A ES200402635 A ES 200402635A ES 200402635 A ES200402635 A ES 200402635A ES 2325344 A1 ES2325344 A1 ES 2325344A1
Authority
ES
Spain
Prior art keywords
multifunctional
angiogenesis inhibitors
multivalent
angiogenesis
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200402635A
Other languages
English (en)
Other versions
ES2325344B1 (es
Inventor
Vallina Luis Alvarez
Lobo Victor Javier Sanchez-Arevalo
Martinez Angel Cuesta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad Autonoma de Madrid
Original Assignee
Universidad Autonoma de Madrid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200402635A priority Critical patent/ES2325344B1/es
Application filed by Universidad Autonoma de Madrid filed Critical Universidad Autonoma de Madrid
Priority to ES05806365T priority patent/ES2339366T3/es
Priority to BRPI0517928-9A priority patent/BRPI0517928A/pt
Priority to EP05806365A priority patent/EP1814993B1/en
Priority to CN2005800381233A priority patent/CN101065486B/zh
Priority to JP2007539527A priority patent/JP2008527974A/ja
Priority to AU2005300737A priority patent/AU2005300737B2/en
Priority to DE602005018812T priority patent/DE602005018812D1/de
Priority to PCT/EP2005/011714 priority patent/WO2006048252A1/en
Priority to CA002585282A priority patent/CA2585282A1/en
Priority to PT05806365T priority patent/PT1814993E/pt
Priority to US11/718,390 priority patent/US20070253952A1/en
Priority to AT05806365T priority patent/ATE454454T1/de
Priority to RU2007120521/13A priority patent/RU2398878C2/ru
Publication of ES2325344A1 publication Critical patent/ES2325344A1/es
Application granted granted Critical
Publication of ES2325344B1 publication Critical patent/ES2325344B1/es
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Los inhibidores de angiogénesis multifuncionales y multivalentes están constituidos por proteínas de fusión que comprenden un polipéptido que reconoce y bloquea una región funcionalmente activa de una molécula implicada en el proceso de angiogénesis, y un polipéptido que comprende un dominio de oligomerización y una región funcionalmente activa, inhibidora o moduladora del proceso de angiogénesis, separados por una región sensible a proteinasas. De aplicación en el tratamiento y prevención de patologías que cursan con procesos de angiogénesis, por ejemplo, cáncer, artritis reumática o psoriasis.
ES200402635A 2004-11-02 2004-11-02 Inhibidores de angiogenesis multifuncionales y multivalentes. Active ES2325344B1 (es)

Priority Applications (14)

Application Number Priority Date Filing Date Title
ES200402635A ES2325344B1 (es) 2004-11-02 2004-11-02 Inhibidores de angiogenesis multifuncionales y multivalentes.
PT05806365T PT1814993E (pt) 2004-11-02 2005-10-31 Inibidores de angiogénese multifuncionais e multivalentes
EP05806365A EP1814993B1 (en) 2004-11-02 2005-10-31 Multifunctional and multivalent angiogenesis inhibitors
CN2005800381233A CN101065486B (zh) 2004-11-02 2005-10-31 多功能和多价的血管生成抑制剂
JP2007539527A JP2008527974A (ja) 2004-11-02 2005-10-31 多機能性多価血管新生阻害薬
AU2005300737A AU2005300737B2 (en) 2004-11-02 2005-10-31 Multifunctional and multivalent angiogenesis inhibitors
DE602005018812T DE602005018812D1 (de) 2004-11-02 2005-10-31 Multifunktionelle und multivalente angiogenese-inhibitoren
PCT/EP2005/011714 WO2006048252A1 (en) 2004-11-02 2005-10-31 Multifunctional and multivalent angiogenesis inhibitors
ES05806365T ES2339366T3 (es) 2004-11-02 2005-10-31 Inhibidores de angiogenesis multifuncionales y multivalentes.
BRPI0517928-9A BRPI0517928A (pt) 2004-11-02 2005-10-31 inibidores multifuncionais e multivalentes de angiogênese
US11/718,390 US20070253952A1 (en) 2004-11-02 2005-10-31 Multifunctional and Multivalent Angiogenesis Inhibitors
AT05806365T ATE454454T1 (de) 2004-11-02 2005-10-31 Multifunktionelle und multivalente angiogenese- inhibitoren
RU2007120521/13A RU2398878C2 (ru) 2004-11-02 2005-10-31 Многофункциональные и поливалентные ингибиторы ангиогенеза
CA002585282A CA2585282A1 (en) 2004-11-02 2005-10-31 Multifunctional and multivalent angiogenesis inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200402635A ES2325344B1 (es) 2004-11-02 2004-11-02 Inhibidores de angiogenesis multifuncionales y multivalentes.

Publications (2)

Publication Number Publication Date
ES2325344A1 true ES2325344A1 (es) 2009-09-01
ES2325344B1 ES2325344B1 (es) 2010-06-09

Family

ID=35592070

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200402635A Active ES2325344B1 (es) 2004-11-02 2004-11-02 Inhibidores de angiogenesis multifuncionales y multivalentes.
ES05806365T Active ES2339366T3 (es) 2004-11-02 2005-10-31 Inhibidores de angiogenesis multifuncionales y multivalentes.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES05806365T Active ES2339366T3 (es) 2004-11-02 2005-10-31 Inhibidores de angiogenesis multifuncionales y multivalentes.

Country Status (13)

Country Link
US (1) US20070253952A1 (es)
EP (1) EP1814993B1 (es)
JP (1) JP2008527974A (es)
CN (1) CN101065486B (es)
AT (1) ATE454454T1 (es)
AU (1) AU2005300737B2 (es)
BR (1) BRPI0517928A (es)
CA (1) CA2585282A1 (es)
DE (1) DE602005018812D1 (es)
ES (2) ES2325344B1 (es)
PT (1) PT1814993E (es)
RU (1) RU2398878C2 (es)
WO (1) WO2006048252A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580755B2 (en) * 2008-02-19 2013-11-12 University Of Rochester Methods and compositions for treating inflammatory conditions
TW201012473A (en) * 2008-09-22 2010-04-01 Tty Biopharm Co Ltd Composition of inhibiting pathological angiogenesis
WO2010122181A1 (es) * 2009-04-20 2010-10-28 Universidad Autónoma de Madrid Proteínas oligoméricas y sus aplicaciones
US9503931B2 (en) 2009-08-12 2016-11-22 Qualcomm Incorporated Enhancements to the MU-MIMO VHT preamble to enable mode detection
WO2011076095A1 (en) * 2009-12-21 2011-06-30 Tty Biopharm Company Limited Methods and compositions related to reduced met phosphorylation by leukocyte cell-derived chemotaxin 2 in tumor cells
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
US20150139991A1 (en) * 2010-10-15 2015-05-21 Leadartis, S.L. Generation of multifunctional and multivalent polypeptide complexes with collagen xviii trimerization domain
EP2441776A1 (en) 2010-10-15 2012-04-18 Leadartis, S.L. Generation of multifunctional and multivalent polypeptide complexes with collagen XVIII trimerization domain
EP2561888A1 (en) * 2011-08-23 2013-02-27 Deutsches Krebsforschungszentrum Protein comprising NC-1 for treating angiogenesis-related diseases
CA2987884C (en) * 2015-06-28 2023-01-03 Allgenesis Biotherapeutics Inc. Fusion peptides comprising disintegrin binding to integrin .alpha.v.beta.x or .alpha.5.beta.1 and their use in treating an angiogenic disease
US20230227568A1 (en) 2020-06-05 2023-07-20 Pieris Pharmaceuticals Gmbh Multimeric immunomodulator targeting 4-1bb

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030054409A1 (en) * 1999-01-12 2003-03-20 Valerie Jerome Novel complex-forming proteins
US20030139365A1 (en) * 1998-08-25 2003-07-24 Kin-Ming Lo Expression and export of angiogenesis inhibitors as immunofusins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1037983A1 (en) * 1997-12-08 2000-09-27 Beth Israel Deaconess Medical Center Mutants of endostatin, "em 1" having anti-angiogenic activity and methods of use thereof
CA2372053C (en) * 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
JP2005516607A (ja) * 2002-02-07 2005-06-09 デルタ バイオテクノロジー リミテッド Ｈｉｖ阻害タンパク質
WO2003091447A2 (en) * 2002-04-26 2003-11-06 California Institute Of Technology D1-1 nucleic acids, polypeptides and related methods
JP2005537032A (ja) * 2002-08-27 2005-12-08 コンパウンド セラピューティクス インコーポレーティッド アドザイムおよびその用途
WO2005021710A2 (en) * 2003-06-02 2005-03-10 University Of Miami Chimeric molecules and methods of use
ES2539126T3 (es) * 2004-12-09 2015-06-26 Janssen Biotech, Inc. Inmunoconjugados anti integrina, métodos para su producción y su uso

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030139365A1 (en) * 1998-08-25 2003-07-24 Kin-Ming Lo Expression and export of angiogenesis inhibitors as immunofusins
US20030054409A1 (en) * 1999-01-12 2003-03-20 Valerie Jerome Novel complex-forming proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SANZ, L. et al. "Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage- derived human antibody fragments blocking functionally active sites of cell-associated matrices". GENE THERAPY. 2002, Vol. 9, páginas 1049-1053, todo el documento. *

Also Published As

Publication number Publication date
EP1814993A1 (en) 2007-08-08
WO2006048252A1 (en) 2006-05-11
JP2008527974A (ja) 2008-07-31
DE602005018812D1 (de) 2010-02-25
CA2585282A1 (en) 2006-05-11
ATE454454T1 (de) 2010-01-15
EP1814993B1 (en) 2010-01-06
BRPI0517928A (pt) 2008-10-21
CN101065486A (zh) 2007-10-31
CN101065486B (zh) 2011-08-31
ES2339366T3 (es) 2010-05-19
RU2007120521A (ru) 2008-12-10
US20070253952A1 (en) 2007-11-01
RU2398878C2 (ru) 2010-09-10
ES2325344B1 (es) 2010-06-09
AU2005300737A1 (en) 2006-05-11
AU2005300737B2 (en) 2011-05-19
PT1814993E (pt) 2010-04-12

Similar Documents

Publication Publication Date Title
ATE454454T1 (de) Multifunktionelle und multivalente angiogenese- inhibitoren
CY1122346T1 (el) Μονοκλωνα αντισωματα εναντι tης κλαουδινης 18 για τη θεραπεια του καρκινου
MX2022009947A (es) Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos.
JO3134B1 (ar) مثبطات نشاط akt
TW200607505A (en) Fused heterocyclic kinase inhibitors
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
ECSP067014A (es) Modulación de producción de inmunoglobulina y trastornos atópicos
NO20080626L (no) Inhibitorer av fibroblastaktiverende protein alfa
DK1553975T3 (da) Optimerede Fc-varianter og fremgangsmåder til generering heraf.
EA200801301A1 (ru) ИНГИБИТОРЫ АКТИВНОСТИ Akt
BR112012011529A2 (pt) sistema de laser, e, método para escanear um feixe de laser
EA200300793A1 (ru) Производные 3-(4-амидопиррол-2-илметилиден)-2-индолинона в качестве ингибиторов протеинкиназ
CR10273A (es) "anticuerpos anti-5t4 y usos de los mismos"
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
WO2007149523A3 (en) Hexahydro-isoalpha acid based protein kinase modulation cancer treatment
MX2009012282A (es) Estructuras cristalinas de fragmentos de neuropilina y complejos de neuropilina-anticuerpos.
MX2021003187A (es) Inhibición de la peptidasa específica de ubiquitina 9x.
NO20082240L (no) GLP-2 imitatorstoff, polypeptider, sammensetninger, fremgangsmater og anvendelser
WO2009158374A3 (en) Inhibitors of akt activity
NZ745999A (en) Anti-tnfalpha-antibodies and functional fragments thereof
ECSP045021A (es) Terapia de combinacion para el tratamiento del cancer
WO2014165277A3 (en) POTENT AND SELECTIVE INHIBITORS OF Nav1.7
WO2005076972A3 (en) Chimeric vegf peptides
NO20055210D0 (no) Inhibitorproteiner av en protease og anvendelse derav
CR20230178A (es) Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20090901

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2325344B1

Country of ref document: ES